comparemela.com

Latest Breaking News On - David lanfear - Page 1 : comparemela.com

Letters to the Editor (1/24/24)

'Carpetbagger' Candidate [Re "Former Middlebury Selectboard Member Announces Bid for Governor," January 5, online]: A 33-year-old from Connecticut running for governor of Vermont? Are you.

South royaltonUnited statesClarendon springsAnne wallace allenDavid lanfearEben markowskiNils daulaireBen lawrenceJonathan gibsonFred tuttleRob mannUniversity of vermont medical centerVermont agency of agricultureMan withVermont agencyGreen water

Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients

/PRNewswire/ Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health.

United statesDavid lanfearPhil febboDavid mcalpineHenry fordIllumina incChristopher jeffries centerDrug administrationWorld health organizationGenomic medicine research at henry ford healthHenry ford healthAmerican college of medical geneticistsClinical pharmacogenetics implementation consortiumDivision of cardiovascular medicine at henry fordCardiovascular medicinePrecision medicine

Study to measure the impact of whole genome sequencing in patients with cardiovascular disease

Henry Ford Health research teams are launching a series of clinical studies in partnership with Illumina Inc., a global leader in DNA sequencing and array-based technologies, to assess the impact of comprehensive genomic testing in various disease areas.

United statesHerb aronowPhil febboEmily hendersonDavid lanfearAmerican college of medical geneticistsWorld health organizationTranslational research at henry ford healthHenry ford healthDrug administrationHeart vascular services at henry ford healthClinical pharmacogenetics implementation consortiumChristopher jeffries centerGenomic medicine research at henry ford healthIllumina incFord health

Illumina, Henry Ford Health Partner on Genomic Testing for Cardiovascular Patients

The partnership could yield data to support the use of whole-genome sequencing in treating and managing cardiovascular disease, the leading cause of death in the US.

David lanfearHenry fordDrug administrationHenry ford healthClinical pharmacogenetics implementation consortiumAmerican college of medical geneticistsFulgent geneticsAmerican collegeMedical geneticists

V-Wave Completes Enrollment in the RELIEVE-HF Randomized Double-Blind Controlled Trial of Interatrial Shunting for Heart Failure

The RELIEVE-HF trial of the Ventura Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure

David lanfearNeal eiglerJames januzziSaibal karJoann lindenfeldJohn gorcsanRichard holcombStephan ankerMichael zileWilliamt abrahamNasrien ibrahimInteratrial shuntVentura shuntBreakthrough device designationChief medicalExecutive committee

vimarsana © 2020. All Rights Reserved.